Genovis rights issue oversubscribed by 63 %

The issue was subscribed for SEK 23,148,827, which it was oversubscribed by 63
%.
Of the total issue volume of 14,563,768 shares, 96 % were subscribed for with
preferential rights. The rights issue raised about SEK 14.5 million before issue
expenses for Genovis. Statements of account will be sent on June 5, 2015, to
allot shares subscribed for without preferential rights.
For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046
(0)46 -101233 fredrik.olsson@genovis.com (sarah.fredriksson@genovis.com)
ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative
technologies that facilitate and enable development of new treatment methods and
diagnostics for customers in the medical device and pharmaceutical industries.
The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis
develops and sells unique enzymes in innovative product formats that facilitate
development and quality control of and biological drugs. GeccoDots uses
nanotechnology to produce a new type of contrast agent that is used in medical
imaging.

Genovis shares are listed on NASDAQ Stockholm First North, and Consensus is
Certified Adviser for the Company, t: 46 (0)31-745 50 00.

This press release is a translation of the Swedish original. In the event of any
discrepancy between this translation and the Swedish original,
the Swedish version shall prevail.